## Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP): Community Acquired Pneumonia

## **Community Acquired Pneumonia (CAP)**

- 1. Community acquired pneumonia is defined as infiltrate on CXR or CT scan with compatible symptoms.
- 2. Antibiotics are NOT usually recommended for exacerbation of asthma or bronchitis with normal chest X-ray or aspiration with normal CXR.
- 3. Nursing home patients presenting with pneumonia should be treated as CAP as outlined below and NOT automatically treated with piperacillin/tazobactam **unless** history of antibiotic resistant organisms or within 14 days of discharge from hospital.
- 4. The CURB-65 score, in conjunction with clinical judgement, is a severity assessment tool for Community Acquired Pneumonia.
- 5. Laboratory testing for respiratory viruses should be considered, including COVID-19, and, during relevant season, influenza and Respiratory Syncytial Virus (RSV). Appropriate treatment for <a href="COVID-19">COVID-19</a> or <a href="influenza">influenza</a> ashould be initiated if positive.

Culture sputum and blood if severe infection **OR** risk factors for MRSA or Pseudomonas infections:

- · ICU admission
- Hospitalised and/or IV antibiotics within past 90 days
- Previous Infection with MRSA or Pseudomonas
- 7. Give antibiotics as soon as possible, within 4 hours of presentation in the Emergency Department.


| Empiric Antibiotics for Con |                                   |                                  |  |   |  |
|-----------------------------|-----------------------------------|----------------------------------|--|---|--|
| Infection                   | 1 st Line Antibiotics             | Penicillin allergy:              |  | Penicillin allergy:                     | Comment  |
|                             |                                   | delayed onset non-seve           |  | immediate or severe<br>delayed reaction |  |
|                             |                                   | See penicillin hypersensit       | ivity section for further info                     | ormation                                | 1  |
| Community                   | Mild CURB-65 Score 0 c            | or 1                             |  |   |  |
|                             | Amoxicillin PO 1g every           | Doxycycline PO 100mg e           | very 12 hours                                      |   | Duration   |
|                             | 8 hours                           | Avaid Dave evaluation in pres    |  | Diagraphia Migraphia I agr              |  |
| (including                  | In younger patients Add           | or Infectious Diseases.          | mancy or breast-reeding.                           | Discuss with Microbiology               | 5 days   |
| nurcing home                | atypical cover with               | Di illiectious Diseases.         |  |   |  |
| patients                    | atypical cover with               |                                  |  |   | (provided afebrile and                           |
|                             | Clarithromycin PO                 |                                  |  |   | clinically stable for 48                         |
|                             | 500mg every 12 hours              |                                  |  |   | hours. Otherwise 7 days)                         |
| Within 17 days              | Moderate <u>CURB-65</u> Sco       |                                  |  |   |  |
| of discharge                | Non-smokers with no               | Levofloxacin PO (IV if NP        | O) 500mg every 12 hours                            |   |  |
| from hospital).             | co-morbidities                    | Avoid <u>Levofloxacin</u> in pre | nancy or breast-feeding                            | Discuss with Micro/ID                   |  |
| See note on                 | Amoxicillin PO/IV 1g              | Caution if risks for prolon      |  |   |  |
|                             | every 8 hours                     |                                  | ,  |   |  |
| Signs and                   |                                   |                                  |  |   |  |
| symptoms of                 | <b>†</b>                          |                                  |  |   |  |
|                             | Clarithromycin PO (IV if          |                                  |  |   | Duration   |
|                             | NPO) 500mg every 12               |                                  |  |   | 5 days   |
| AND new                     | hours                             |                                  |  |   |  |
| consolidation               | B-111                             |                                  |  |   | (provided afebrile and                           |
| on chost A ray              | Patients who smoke<br>and/or with |                                  |  |   | clinically stable for 48 hours. Otherwise 7 days |
|                             | co-morbidities                    |                                  |  |   | nours. Otherwise 7 days                          |
|                             | o morbianio                       |                                  |  |   | ľ  |
|                             | Co-amoxiclav PO                   |                                  |  |   | Most patients can be                             |
|                             | 875/125mg every 8                 |                                  |  |   | treated with oral                                |
|                             | hours/IV 1.2g every 8             |                                  |  |   | antibiotics                                      |
|                             | hours                             |                                  |  |   |  |
|                             | +                                 |                                  |  |   |  |
|                             | Clarithromycin PO (IV if          |                                  |  |   |  |
|                             | NPO) 500mg every 12               |                                  |  |   |  |
|                             | hours                             |                                  |  |   |  |
|                             | Severe CURB-65 Score              | <u>l</u><br>≥ 3                  |  |   | l  |
|                             | Co-amoxiclav IV 1.2g              | CefTRIAXone IV 2g                | Levofloxacin PO (IV if NP                          | O) 500mg every 12 hours                 | Duration   |
|                             | every 8 hours                     | every 24 hours                   |  |   |  |
|                             |                                   |                                  | Avoid levofloxacin in preg                         |   | 7 days   |
|                             | †                                 | <b>†</b>                         | Discuss with Micro/ID. (<br>prolonged QT interval. | Jaution if risks for                    | Longer courses may be                            |
|                             | Clarithromycin PO (IV if          | Clarithromycin PO (IV if         | protonged QT Interval.                             |   | indicated according to                           |
|                             | NPO) 500mg every 12               | NPO) 500mg every 12              |  |   | clinical judgement                               |
|                             | hours                             | hours                            |  |   | a a if I agins - !!-                             |
|                             |                                   |                                  |  |   | e.g. if Legionella<br>pneumophila,               |
|                             |                                   |                                  |  |   | Staphylococcus aureus                            |
|                             |                                   |                                  |  |   | or Gram-negative bacilli                         |
|                             |                                   |                                  |  |   | suspected or confirmed.                          |
|                             |                                   |                                  |  |   |  |
|                             |                                   |                                  |  |   | Consider addition of                             |
|                             |                                   |                                  |  |   | steroids for those<br>requiring Non Invasive     |
|                             |                                   |                                  |  |   | Ventilation (NIV)/                               |
|                             |                                   |                                  |  |   | Mechanical Ventilation                           |
|                             |                                   |                                  |  |   | (MV) in consultation with                        |
|                             |                                   |                                  |  |   | Resp/ID.   |
|                             | L                                 | 1                                |  |   |  |

| Galway: GAPP - Galway Antimicrobial Prescribing Policy / Guidelines (GAPP) - Last Updated: Oct. 3, 2025, 5:15 p.m., printed: Oct. 8, 2025, 3:29 |
|---|
| a.m.  |
| page 1 of 2   |

## Refs:

- 1. Community-Acquired Pneumonia. The New England Journal of Medicine. 2023. 389:632-41.
- 2. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care 2019;200(7):e45–e67
- 3. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. <u>JAMA</u> Intern Med 2016;176(9):1257-1265
- 4. British Thoracic Society Guidelines for the management of community acquired pneumonia in adults. Annotated CAP Guideline 2015.

## **CURB-65**



(click on image to enlarge)